InnovaRx Global Health · Investor Portal

Investor Dashboard

InnovaRx Global Health · Kartan Holdings LLC · Investor Portal

Dashboard reflects the most recently closed month. Finance posts the prior month's actuals by the 10th of each new month.

Active WOW Subscribers

—

Tier breakdown loading…

Monthly Revenue (GMD)

—

Historical ceiling: GMD 2.5M

Monthly Revenue (USD)

—

Blended Gross Margin

—%

Pharmacy + subscriptions

Inventory Days-on-Hand

—days

12-medication formulary

GC7 Grant Utilization

—%

YTD disbursement

Bridge Round Raised

—

of $75K minimum close

Series A Milestones

—done

of total

Cash Position & Growth Trajectory

Cash Runway

—

Weeks of cash at current burn

Monthly Net Burn

—

OpEx minus revenue

MoM Revenue Growth

—

vs. prior month

Net New Subscribers

—

Target: 25/month

Revenue by Stream — Current Period

Pharmacy & Clinical

WOW Subscriptions

Subscriber Tier Breakdown

GC7 Global Fund Grant Status

Renewal probability 80–90% · Active through 2027 · Target renewal through 2030

Renewal Tracking

YTD Disbursement—

Annual budget: —

Commercial Revenue ShareTarget: 50%

% of total revenue from commercial operations

Series A Milestones

Proof points for Qualified Financing

◎

Loading…

Latest Investor Update

Most recent quarterly communication

View All →

◎

No updates yet

Cap Table

Fully diluted · As of April 2026 · Post note conversions

1,123,736

Total Fully Diluted Units

24

Total Shareholders

42.16%

Kartan Holdings (Founder)

Founder & Management

Class B Investors

20 holders

SAFEs & Convertible Notes

All outstanding and historical instruments · Kartan Holdings LLC

Outstanding Notes

—

Active instruments

Outstanding Principal

—

Total face value outstanding

Total Converted

—

into equity

Overdue / At-Term

—

Require immediate action

Filter

Convertible Notes

8% p.a. compound interest · $2M valuation cap OR 20% discount (lesser governs)

Loading…

Holder	Principal	Rate	Issue Date	Maturity	Total w/ Interest	Val. Cap	Discount	Status	Units Received

SAFEs

Simple Agreements for Future Equity

Loading…

Holder	Investment	Issue Date	Val. Cap	Discount	MFN	Status	Units Received

Converted Note has converted to equity

Outstanding Active, within term

Overdue Past maturity, unpaid

Extended Maturity extended by agreement

Cash Repaid Repaid at maturity

Quarterly Updates

Investor communications & town hall summaries

◎

No updates posted yet. First quarterly town hall summary will appear here.

Log KPIs

Submit monthly metrics for investor reporting

Subscriber Metrics

Total Active Subscribers

All active WOW subscription holders

WOW ACP (Assurance $800/yr)

Premium RX ($330/yr)

Basic RX ($165/yr)

Solo RX ($100/yr)

Revenue Metrics

Total Monthly Revenue (GMD)

Total commercial revenue in Dalasi

USD Exchange Rate (GMD per $1)

Current market rate

Pharmacy & Clinical Revenue (GMD)

Target ~60% of total

Subscription Revenue (GMD)

Target ~40% of total

Gross Margin % — Pharmacy

Gross Margin % — Subscriptions

Cash Position & Burn

Total Cash on Hand (GMD)

Sum of all unrestricted bank accounts + petty cash + mobile money

Monthly Operating Expenses (GMD)

Total monthly opex from cash forecast (payroll + rent + utilities + supplies + etc.)

Inventory & Grant

Inventory Days-on-Hand (formulary)

GC7 Annual Budget (USD)

GC7 YTD Disbursed (USD)

Bridge Round — Total Raised (USD)

Cumulative to date

Commercial Revenue Mix (%)

Commercial share of total revenue (vs grant)

Enter metrics above and save

Operations

Subscriber and revenue detail — current period

Last updated: —

Active Subscribers

—

Target: 1,000 by Q4 2026

Inventory DOH

—days

12-medication formulary stock

Bridge Round Progress

—

of $75K minimum / $100K target

Subscriber Tier Detail

Current period

Tier	Annual Price	Subscribers	Share	Est. Annual Rev (GMD)

Revenue Breakdown

Stream	GMD	USD	Gross Margin %	Share

Notes & SAFEs

Active convertible instruments · Interest accrual · Conversion tracking

—

Total Principal (USD)

—

Total w/ Accrued Interest

—

Active Instruments

—

Past Due / Matured

Convertible Notes

Compound interest · 8% p.a. · $2M valuation cap OR 20% discount to qualified financing price

0 active

Noteholder	Principal	Rate	Issued	Maturity	Accrued Int.	Total Outstanding	Status	Notes

SAFEs

Simple Agreement for Future Equity · No maturity date · Converts on qualified financing

0 active

Investor	Investment	Val. Cap	Discount %	Date	MFN	Pro-Rata	Status	Notes

Conversion Calculator

Model conversion price at different Series A valuations

Series A Pre-Money Valuation (USD)

e.g. 7,500,000 for $7.5M pre-money

Series A Round Size (USD)

Pre-Conversion FD Units

Valuation Cap (USD)

From note agreement §3(a)

Enter values above to model conversion price.

My Convertible Note

Your standing with InnovaRx Global Health · Kartan Holdings LLC

Last updated: —

Original Principal

—

Issued: —

Accrued Interest

—

— · —

Total Paid

—

— payments recorded

Balance Owed

—

Status: —

Note Terms

Reference detail from your convertible note agreement

Maturity Date

—

Interest Type

—

Term

—

Valuation Cap

—

Discount

—

Note Status

—

Payment Schedule

Installment plan agreed with InnovaRx Global Health

Payment History

All payments recorded against your note

Date	Method	Reference	Amount (USD)

Latest Company Update

Most recent quarterly communication from leadership

◎

No updates posted yet

Admin Panel

User access · Milestones · Investor communications

Portal Users

Manage investor, finance, and operations access

Loading users…

Series A Milestones

Update milestone status visible to all investors

Loading…

Convertible Notes & SAFEs Data

Import all 37 noteholders + 3 SAFEs from the master spreadsheet. Safe to run multiple times — duplicates are skipped.

8% compound · $2M cap · 20% discount

Post Quarterly Update

Visible to all portal users

Quarter

Update Title

Content